Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma

Inclusion Criteria: * Stage II or III multiple myeloma according to Durie and Salmon criteria, patients older than 75 years, previously untreated patients. Exclusion Criteria: * Prior history of another neoplasm (except basocellular cutaneous or cervical epithelioma) * Primary or associated amyloïdosis * World Health organisation performance index of at least 3 * Significant renal insufficiency with creatinine serum levels of 5.0 mg per deciliter or more * Cardiac or hepatic dysfunction * Cerebral circulatory insufficiency * Absolute contraindication to corticosteroids * Peripheral neuropathy clinically significant * History of venous thrombosis during the last 6 months * HIV or hepatitis B or C positivity * Patients who had geography, social, or psychological conditions which might prevent adequate follow-up.